1. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Issue 12 (December 2020) Authors: Tacchetti, Paola; Pantani, Lucia; Patriarca, Francesca; Petrucci, Maria Teresa; Zamagni, Elena; Dozza, Luca; Galli, Monica; Di Raimondo, Francesco; Crippa, Claudia; Boccadoro, Mario; Barbato, Simona; Tosi, Patrizia; Narni, Franco; Montefusco, Vittorio; Testoni, Nicoletta; Spadano, Antonio; Terrag... Journal: Lancet Issue: Volume 7:Issue 12(2020) Page Start: e861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bortezomib‐ and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Issue 12 (17th September 2014) Authors: Tacchetti, Paola; Terragna, Carolina; Galli, Monica; Zamagni, Elena; Petrucci, Maria Teresa; Pezzi, Annalisa; Montefusco, Vittorio; Martello, Marina; Tosi, Patrizia; Baldini, Luca; Peccatori, Jacopo; Ruggieri, Miriana; Pantani, Lucia; Lazzaro, Antonio; Elice, Francesca; Rocchi, Serena; Gozzetti, ... Journal: American journal of hematology Issue: Volume 89:Issue 12(2014:Dec.) Page Start: 1085 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Characteristics and outcomes of five patients with COVID‐19 and hematological malignancies. Issue 6 (10th June 2021) Authors: Citterio, Chiara; Lazzaro, Antonio; Bosi, Costanza; De Ponzio, Maurice; Cavanna, Luigi Journal: Clinical case reports Issue: Volume 9:Issue 6(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Issue 2 (February 2022) Authors: Schjesvold, Fredrik H; Dimopoulos, Meletios-Athanasios; Delimpasi, Sosana; Robak, Pawel; Coriu, Daniel; Legiec, Wojciech; Pour, Luděk; Špička, Ivan; Masszi, Tamas; Doronin, Vadim; Minarik, Jiri; Salogub, Galina; Alekseeva, Yulia; Lazzaro, Antonio; Maisnar, Vladimir; Mikala, Gábor; Rosiñol, Laura;... Journal: Lancet Issue: Volume 9:Issue 2(2022) Page Start: e98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Issue 7 (July 2018) Authors: Moreau, Philippe; Mateos, Maria-Victoria; Berenson, James R; Weisel, Katja; Lazzaro, Antonio; Song, Kevin; Dimopoulos, Meletios A; Huang, Mei; Zahlten-Kumeli, Anita; Stewart, A Keith Journal: Lancet oncology Issue: Volume 19:Issue 7(2018) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗